Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus chemotherapy induction in elderly esophageal squamous cell carcinoma
ChiCTR2400091792Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: clinical complete response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400091792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091792.